IL205776A0 - Morpholino compounds and methods of producing morpholino oligomers - Google Patents

Morpholino compounds and methods of producing morpholino oligomers

Info

Publication number
IL205776A0
IL205776A0 IL205776A IL20577610A IL205776A0 IL 205776 A0 IL205776 A0 IL 205776A0 IL 205776 A IL205776 A IL 205776A IL 20577610 A IL20577610 A IL 20577610A IL 205776 A0 IL205776 A0 IL 205776A0
Authority
IL
Israel
Prior art keywords
morpholino
methods
producing
compounds
oligomers
Prior art date
Application number
IL205776A
Other languages
English (en)
Original Assignee
Avi Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc filed Critical Avi Biopharma Inc
Publication of IL205776A0 publication Critical patent/IL205776A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL205776A 2007-11-15 2010-05-13 Morpholino compounds and methods of producing morpholino oligomers IL205776A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98820007P 2007-11-15 2007-11-15
US98819207P 2007-11-15 2007-11-15
PCT/US2008/012804 WO2009064471A1 (en) 2007-11-15 2008-11-14 Method of synthesis of morpholino oligomers

Publications (1)

Publication Number Publication Date
IL205776A0 true IL205776A0 (en) 2010-11-30

Family

ID=40293764

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205776A IL205776A0 (en) 2007-11-15 2010-05-13 Morpholino compounds and methods of producing morpholino oligomers

Country Status (13)

Country Link
EP (1) EP2207779B1 (enExample)
JP (3) JP5512533B2 (enExample)
KR (1) KR101617472B1 (enExample)
CN (1) CN101861318A (enExample)
BR (1) BR122019021332A8 (enExample)
CA (2) CA2704261C (enExample)
DK (1) DK2207779T3 (enExample)
ES (1) ES2479393T3 (enExample)
HR (1) HRP20140646T1 (enExample)
IL (1) IL205776A0 (enExample)
MX (1) MX2010004955A (enExample)
RU (1) RU2606627C2 (enExample)
WO (1) WO2009064471A1 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
JP5991922B2 (ja) 2009-11-13 2016-09-14 サレプタ セラピューティクス， インコーポレイテッド アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法
KR102182663B1 (ko) 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
DK2623507T3 (da) * 2010-09-30 2017-01-02 Nippon Shinyaku Co Ltd Morpholinonukleinsyrederivat
EP2638161A1 (en) 2010-11-12 2013-09-18 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
IL273838B (en) 2011-05-05 2022-09-01 Sarepta Therapeutics Inc Peptide and oligonucleotide conjugates, preparations containing them and their uses
EP2732035A2 (en) 2011-07-15 2014-05-21 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
WO2013082548A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
WO2013086441A2 (en) 2011-12-08 2013-06-13 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
CA3132111A1 (en) * 2011-12-28 2013-07-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
JP6542662B2 (ja) 2012-03-20 2019-07-10 サレプタ セラピューティクス， インコーポレイテッド オリゴヌクレオチドアナログのボロン酸結合体
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
EP3015467B1 (en) * 2013-05-24 2024-12-04 Ajinomoto Co., Inc. Morpholino oligonucleotide manufacturing method
KR102275504B1 (ko) 2013-09-05 2021-07-09 사렙타 쎄러퓨틱스, 인코퍼레이티드 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
EP3868772A1 (en) 2013-09-30 2021-08-25 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
RU2730681C2 (ru) 2014-03-12 2020-08-24 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
EP3569252B1 (en) 2014-05-19 2021-12-15 Oregon State University Antisense antibacterial compounds and methods
AU2015277924B2 (en) 2014-06-17 2021-02-25 National Center Of Neurology And Psychiatry Antisense nucleic acids
JP6673211B2 (ja) * 2014-10-14 2020-03-25 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
CA3249464A1 (en) 2014-12-31 2025-11-29 Univ Texas Antisense antibacterial compounds and methods
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
CN114681621B (zh) 2015-05-19 2024-08-06 萨勒普塔医疗公司 肽寡核苷酸缀合物
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN108350005B (zh) * 2015-08-05 2024-02-06 卫材R&D管理有限公司 用于制备均一低聚物的手性试剂
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
HRP20201125T1 (hr) 2015-09-15 2020-10-30 Nippon Shinyaku Co., Ltd. Antisens nukleinska kiselina
WO2017047741A1 (ja) 2015-09-16 2017-03-23 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
JP2018538302A (ja) 2015-12-15 2018-12-27 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチド複合体
JP7393121B2 (ja) 2015-12-23 2023-12-06 オレゴン ステイト ユニバーシティー アンチセンス抗菌化合物および方法
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MY200252A (en) 2016-04-18 2023-12-16 Sarepta Therapeutics Inc Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
WO2017190041A1 (en) 2016-04-29 2017-11-02 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
CA3024178A1 (en) 2016-05-24 2017-12-14 Sarepta Therapeutics, Inc. Pharmaceutical composition comprising eteplirsen
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101834QA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101830WA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
CN109152792B (zh) 2016-06-30 2021-09-14 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
WO2018057430A1 (en) * 2016-09-20 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
EP3554552B1 (en) 2016-12-19 2022-08-17 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
CN117298290A (zh) 2016-12-19 2023-12-29 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MA49986A (fr) 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
KR102898787B1 (ko) 2018-05-10 2025-12-11 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
BR112020026542A2 (pt) 2018-06-26 2021-04-06 Nippon Shinyaku Co., Ltd. Composição que compreende oligonucleotídeo antissenso e uso da mesma para tratamento de distrofia muscular de duchenne
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
IL321667A (en) 2018-12-13 2025-08-01 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
JP7689078B2 (ja) 2019-11-13 2025-06-05 日本新薬株式会社 オリゴ核酸化合物の製造方法
EP4059943A4 (en) 2019-11-13 2024-01-31 Nippon Shinyaku Co., Ltd. METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND
EP4079329A4 (en) 2019-12-19 2024-04-17 Nippon Shinyaku Co., Ltd. ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
CA3165961A1 (en) 2019-12-26 2021-07-01 Nippon Shinyaku Co., Ltd. Antisense nucleic acid that induces skipping of exon 50
AU2021226089A1 (en) 2020-02-28 2022-09-15 National Center Of Neurology And Psychiatry Antisense nucleic acid inducing skipping of exon 51
WO2022006871A1 (en) * 2020-07-10 2022-01-13 Changzhou Syntheall Pharmaceuticals Co., Ltd. Processes for preparing oligonucleotides
JP7825613B2 (ja) 2021-04-28 2026-03-06 日本新薬株式会社 オリゴ核酸化合物の製造方法
US20240287511A1 (en) 2021-05-13 2024-08-29 National University Corporation Chiba University Antisense Oligomer
CN117500925A (zh) 2021-05-28 2024-02-02 住友制药株式会社 反义核酸
AU2022298028A1 (en) 2021-06-23 2023-12-21 National Center Of Neurology And Psychiatry Combination of antisense oligomers
JPWO2023282346A1 (enExample) 2021-07-08 2023-01-12
EP4368186A4 (en) 2021-07-08 2025-06-25 Nippon Shinyaku Co., Ltd. NEPHROTOXICITY REDUCING AGENT
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
US20250011777A1 (en) 2021-09-03 2025-01-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
JP2024537711A (ja) 2021-09-30 2024-10-16 サレプタ セラピューティクス， インコーポレイテッド １つ以上の脱塩基ユニットを有するアンチセンスオリゴヌクレオチド
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
KR20240129006A (ko) 2021-12-27 2024-08-27 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
IL315344A (en) * 2022-03-01 2024-10-01 Eisai R&D Man Co Ltd Bis-protected, activated guanine monomers
JP2025533454A (ja) 2022-09-21 2025-10-07 サレプタ セラピューティクス， インコーポレイテッド Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
TW202442246A (zh) 2023-04-27 2024-11-01 美商薩羅塔治療公司 用於治療慢性腎病之反義寡聚物
WO2025030099A1 (en) 2023-08-02 2025-02-06 Sarepta Therapeutics, Inc. Non-canonical cell-penetrating peptides for antisense oligomer delivery
AU2024362420A1 (en) 2023-10-18 2026-04-23 Murdoch University Antisense oligomers for treatment of centronuclear myopathies
CN117586307B (zh) * 2024-01-19 2024-04-16 凯莱英生命科学技术(天津)有限公司 Pmo鸟苷单体的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH577464A5 (enExample) * 1972-09-22 1976-07-15 Ciba Geigy Ag
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0962463B1 (en) * 1989-12-20 2002-07-10 Antivirals Inc. Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages
WO1991018898A1 (en) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Nucleic acid homolog
US5510476A (en) 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
UA48150C2 (uk) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Похідні амінокислот або аміноспиртів, олігонуклеотид
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
ES2645410T3 (es) * 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos

Also Published As

Publication number Publication date
CA2884340A1 (en) 2009-05-22
BRPI0819828A8 (pt) 2022-12-27
JP2011503184A (ja) 2011-01-27
RU2010123958A (ru) 2011-12-20
AU2008321409B2 (en) 2014-08-14
CN101861318A (zh) 2010-10-13
BR122019021332A8 (pt) 2022-12-06
CA2884340C (en) 2017-07-25
JP5512533B2 (ja) 2014-06-04
JP2014159432A (ja) 2014-09-04
MX2010004955A (es) 2010-06-30
KR101617472B1 (ko) 2016-05-02
CA2704261C (en) 2015-05-26
CA2704261A1 (en) 2009-05-22
BRPI0819828A2 (pt) 2015-05-26
AU2008321409A1 (en) 2009-05-22
HRP20140646T1 (hr) 2014-09-26
HK1144424A1 (en) 2011-02-18
BR122019021332A2 (enExample) 2015-05-26
JP2016196494A (ja) 2016-11-24
RU2606627C2 (ru) 2017-01-10
KR20100090681A (ko) 2010-08-16
JP6178744B2 (ja) 2017-08-09
EP2207779B1 (en) 2014-04-09
EP2207779A1 (en) 2010-07-21
WO2009064471A1 (en) 2009-05-22
DK2207779T3 (da) 2014-07-14
ES2479393T3 (es) 2014-07-24

Similar Documents

Publication Publication Date Title
HRP20190408T1 (hr) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
ZA201002696B (en) Methods of maintaining or increasing growth or cognitive development
GB0711697D0 (en) Method of manufacture
EP2212251A4 (en) PROCESS FOR THE PRODUCTION OF CLUSTERBOR
EP2233548A4 (en) PROCESS FOR PRODUCING FERROCOKE
IL218045A (en) Azididinone compounds, used and production methods
HUP0700421A2 (en) Emulsions based of plant-germ, process for their production and use
EP2144886A4 (en) METHOD OF TREATING MELANOMA
IL243809A (en) Process for the production of γ-ketosulfide compounds and γ-ketosulfide compounds obtained
GB0725348D0 (en) Method of authentication
GB0714290D0 (en) Product and method of manufacture
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
EP2205525A4 (en) PROCESS FOR THE PREPARATION OF CLUSTERBORON
IL183445A0 (en) Continuous process of preparing bromopicrin
TWI319390B (en) Process of producing o-methyl-n-nitroisourea
GB0907249D0 (en) New process and new compounds
PL382168A1 (pl) Sposób wytwarzania S-(-)- 8-metoksy -2 tetralolu
GB0606542D0 (en) Novel compounds and methods for their production
PL384332A1 (pl) Nowe związki fluoflawinowe oraz sposób ich wytwarzania
HUP0700484A3 (en) Nanocomposits of titanate-polymer and method for production thereof
PL382735A1 (pl) Barwne polisacharyniany oraz sposób otrzymywania barwnych polisacharynianów
GB0720875D0 (en) Novel compounds and methods for their production
GB0811062D0 (en) Novel compounds and methods for their production
PL382869A1 (pl) Dicyjanoimidki 3-alkoksymetylo-1-metyloimidazoliowe oraz sposób wytwarzania dicyjanoimidków 3-alkoksymetylo-1-metyloimidazoliowych
PL382723A1 (pl) Barwne krzemionki oraz sposób wytwarzania barwnych krzemionek